NCT07075133Not yet recruiting
Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 24 Jun 2025
- Start date
- 15 Sept 2026
- Primary completion date
- 15 Jul 2029
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07075133
What you commit to
- Study type: Interventional
- Planned participants: 45
- From 15 Sept 2026 to the primary completion date, 15 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects on T2DM injectable medication or drugs able to induce hypoglycemia (glinides, sulfonylurea)
- Subjects with previous or present history of serious eating disorder
- Subjects currently participating or has participated in another study of an investigational medication or an investigational medical device within the last 30 days
- Women with menopause hormone replacement therapy
Lab values
- Subjects with HbA1c \> 8%
- Subjects with any of the following medical conditions:
- Congestive cardiac failure
- Stage 4 chronic kidney disease (i.e. eGFR \< 30 ml/min/1.73 m2)
- Liver cirrhosis or chronic liver disease
- Any medical condition that in the opinion of the investigator could jeopardize or compromise the subject's ability to participate in the study
Other
- Subjects not able to understand the informed consent form or fasting diary instructions
Who the study is looking for
- Post-menopausal women (amenorrhea for at least 12 months, confirmed by gonadotrophins measures)
- Age range 45-70 years
- T2DM diagnosed for more than 1 year
- Subjects with T2DM treated with lifestyle control alone or associated with metformine ± DPP4 inhibitors
- Ability to sign written informed consent before any study-specific procedure
- Subject considered as reliable and capable of adhering to protocol
- Subjects with Body Mass Index (BMI)≥ 30 kg/m²
- Baseline eating period ≥ 14 h per day (as estimated by 95% eating interval)
Age in the registry: 45 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rangueil hospital Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.